Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

October 10, 2007 17:10 ET

Critical Outcome Technologies Inc. Announces the Issuance of Stock Options

LONDON, ONTARIO--(Marketwire - Oct. 10, 2007) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced today, under the Company's Stock Option Plan, the Board of Directors approved the granting of 100,000 stock options to the non-management members of the Company's Scientific Advisory Committee. The exercise price is $2.00 per share and the stock options vested immediately. The exercise price represents the closing price of the Company's common shares on October 5, 2007, as reported on the TSX Venture Exchange.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information